25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

AGY (Allergy Therapeutics) Stock Analysis
Buy, Hold or Sell?

Let's analyze Allergy Therapeutics together

I guess you are interested in Allergy Therapeutics. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

  • ๐Ÿ“Š Fundamental Analysis (FA) โ€“ Allergy Therapeuticsโ€™s Financial Insights
  • ๐Ÿ“ˆ Technical Analysis (TA) โ€“ Allergy Therapeuticsโ€™s Price Targets

I'm going to help you getting a better view of Allergy Therapeutics. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Allergy Therapeutics

I send you an email if I find something interesting about Allergy Therapeutics.

1. Quick Overview

1.1. Quick analysis of Allergy Therapeutics (30 sec.)










1.2. What can you expect buying and holding a share of Allergy Therapeutics? (30 sec.)

How much money do you get?

How much money do you get?
p0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
p0.08
Expected worth in 1 year
p0.22
How sure are you?
50.0%

+ What do you gain per year?

Total Gains per Share
p0.14
Return On Investment
1.7%

For what price can you sell your share?

Current Price per Share
p8.25
Expected price per share
p8 - p
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Allergy Therapeutics (5 min.)




Live pricePrice per Share (EOD)
p8.25
Intrinsic Value Per Share
p-15.27 - p-5.04
Total Value Per Share
p-15.19 - p-4.96

2.2. Growth of Allergy Therapeutics (5 min.)




Is Allergy Therapeutics growing?

Current yearPrevious yearGrowGrow %
How rich?$5m$2.8m$2.2m44.3%

How much money is Allergy Therapeutics making?

Current yearPrevious yearGrowGrow %
Making money-$54.6m-$58.5m$3.8m7.1%
Net Profit Margin-72.9%-72.3%--

How much money comes from the company's main activities?

2.3. Financial Health of Allergy Therapeutics (5 min.)




3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Allergy Therapeutics?

Welcome investor! Allergy Therapeutics's management wants to use your money to grow the business. In return you get a share of Allergy Therapeutics.

First you should know what it really means to hold a share of Allergy Therapeutics. And how you can make/lose money.

Speculation

The Price per Share of Allergy Therapeutics is p8.25. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Allergy Therapeutics.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Allergy Therapeutics, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is p0.08. Based on the TTM, the Book Value Change Per Share is p0.03 per quarter. Based on the YOY, the Book Value Change Per Share is p-0.75 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is p0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Allergy Therapeutics.

How much money are you going to get?

 MRQTTMYOY3Y5Y10Y
 p% of Price per Sharep% of Price per Sharep% of Price per Sharep% of Price per Sharep% of Price per Sharep% of Price per Share
Usd Eps-0.01-0.1%-0.01-0.1%-0.01-0.2%-0.01-0.1%-0.01-0.1%0.000.0%
Usd Book Value Change Per Share0.000.0%0.000.0%-0.01-0.1%0.00-0.1%0.000.0%0.000.0%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share0.000.0%0.000.0%-0.01-0.1%0.00-0.1%0.000.0%0.000.0%
Usd Price Per Share0.07-0.07-0.01-0.12-0.18-0.24-
Price to Earnings Ratio-6.21--6.21--0.98--26.33-85.69-953.67-
Price-to-Total Gains Ratio152.02-152.02--1.40-19.59-83.35--329.28-
Price to Book Ratio67.34-67.34-24.22-39.25-31.51-33.39-
Price-to-Total Gains Ratio152.02-152.02--1.40-19.59-83.35--329.28-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.11210925
Number of shares8919
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.000.00
Usd Total Gains Per Share0.000.00
Gains per Quarter (8919 shares)4.18-17.21
Gains per Year (8919 shares)16.71-68.86
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
101770-69-79
2033240-138-148
3050410-207-217
4067580-275-286
5084750-344-355
60100920-413-424
701171090-482-493
801341260-551-562
901501430-620-631
1001671600-689-700

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.01.00.00.0%0.03.00.00.0%2.03.00.040.0%4.06.00.040.0%10.013.00.043.5%
Book Value Change Per Share1.00.00.0100.0%1.02.00.033.3%3.02.00.060.0%5.05.00.050.0%13.010.00.056.5%
Dividend per Share0.00.01.00.0%0.00.03.00.0%0.00.05.00.0%0.00.010.00.0%0.00.023.00.0%
Total Gains per Share1.00.00.0100.0%1.02.00.033.3%3.02.00.060.0%5.05.00.050.0%13.010.00.056.5%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Allergy Therapeutics compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-3Y+/-5 Year+/-10 Year+/-
Book Value Change Per Share--0.0340.0340%-0.749+2273%-0.313+1009%-0.142+512%-0.024+169%
Book Value Per Share--0.0780.0780%0.043+80%0.304-74%0.570-86%0.611-87%
Current Ratio--1.6301.6300%1.806-10%1.928-15%2.397-32%2.709-40%
Debt To Asset Ratio--0.9430.9430%0.969-3%0.798+18%0.667+41%0.560+68%
Debt To Equity Ratio--16.47816.4780%31.318-47%16.243+1%10.102+63%5.480+201%
Dividend Per Share----0%-0%-0%-0%-0%
Enterprise Value--20155845264.64020155845264.6400%18961932.800+106196%39203878623.147-49%60605338674.688-67%81716971644.544-75%
Eps---0.844-0.8440%-1.071+27%-0.734-13%-0.399-53%-0.240-72%
Ev To Ebitda Ratio---6.557-6.5570%-0.005-100%-39.562+503%18.930-135%-379.278+5684%
Ev To Sales Ratio--3.6513.6510%0.003+114646%5.682-36%7.929-54%12.950-72%
Free Cash Flow Per Share---0.746-0.7460%-0.747+0%-0.617-17%-0.305-59%-0.185-75%
Free Cash Flow To Equity Per Share---0.086-0.0860%-0.119+38%-0.207+140%-0.067-22%0.022-501%
Gross Profit Margin--1.4871.4870%1.550-4%1.975-25%-0.866+158%-14.909+1103%
Intrinsic Value_10Y_max---5.038----------
Intrinsic Value_10Y_min---15.270----------
Intrinsic Value_1Y_max---0.254----------
Intrinsic Value_1Y_min---0.856----------
Intrinsic Value_3Y_max---0.955----------
Intrinsic Value_3Y_min---3.172----------
Intrinsic Value_5Y_max---1.886----------
Intrinsic Value_5Y_min---6.126----------
Market Cap39323129472.000+36%24976145264.64024976145264.6400%5004761932.800+399%42961511956.480-42%62955138674.688-60%83074281644.544-70%
Net Profit Margin---0.729-0.7290%-0.723-1%-0.547-25%-0.303-58%-0.189-74%
Operating Margin---0.635-0.6350%-0.679+7%-0.497-22%-0.270-57%-0.165-74%
Operating Ratio--1.6391.6390%1.585+3%1.467+12%1.263+30%1.163+41%
Pb Ratio106.021+36%67.33967.3390%24.224+178%39.251+72%31.509+114%33.386+102%
Pe Ratio-9.778-57%-6.210-6.2100%-0.981-84%-26.328+324%85.691-107%953.667-101%
Price Per Share8.250+36%5.2405.2400%1.050+399%9.013-42%13.208-60%17.429-70%
Price To Free Cash Flow Ratio-11.065-57%-7.028-7.0280%-1.406-80%-22.016+213%40.536-117%-26.827+282%
Price To Total Gains Ratio239.337+36%152.015152.0150%-1.402+101%19.594+676%83.348+82%-329.280+317%
Quick Ratio--1.0091.0090%1.181-15%1.302-22%1.786-43%1.969-49%
Return On Assets---0.620-0.6200%-0.645+4%-0.485-22%-0.268-57%-0.171-72%
Return On Equity---10.843-10.8430%-20.848+92%-10.685-1%-6.367-41%-3.258-70%
Total Gains Per Share--0.0340.0340%-0.749+2273%-0.313+1009%-0.142+512%-0.024+169%
Usd Book Value--5040160.1005040160.1000%2807487.400+80%19722168.667-74%36923487.240-86%39572255.120-87%
Usd Book Value Change Per Share--0.0000.0000%-0.010+2273%-0.004+1009%-0.002+512%0.000+169%
Usd Book Value Per Share--0.0010.0010%0.001+80%0.004-74%0.008-86%0.008-87%
Usd Dividend Per Share----0%-0%-0%-0%-0%
Usd Enterprise Value--273897781.301273897781.3010%257673.705+106196%532741506.610-49%823565947.250-67%1110451927.678-75%
Usd Eps---0.011-0.0110%-0.015+27%-0.010-13%-0.005-53%-0.003-72%
Usd Free Cash Flow---48293947.100-48293947.1000%-48356456.500+0%-39992879.967-17%-19733402.240-59%-11956417.540-75%
Usd Free Cash Flow Per Share---0.010-0.0100%-0.010+0%-0.008-17%-0.004-59%-0.003-75%
Usd Free Cash Flow To Equity Per Share---0.001-0.0010%-0.002+38%-0.003+140%-0.001-22%0.000-501%
Usd Market Cap534362006.395+36%339400838.001339400838.0010%68009709.905+399%583803985.977-42%855497379.450-60%1128896413.268-70%
Usd Price Per Share0.112+36%0.0710.0710%0.014+399%0.122-42%0.179-60%0.237-70%
Usd Profit---54649522.400-54649522.4000%-58529181.900+7%-43966303.567-20%-23677201.820-57%-14489950.700-73%
Usd Revenue--75009921.10075009921.1000%80972774.300-7%84955710.200-12%95147188.420-21%88060660.810-15%
Usd Total Gains Per Share--0.0000.0000%-0.010+2273%-0.004+1009%-0.002+512%0.000+169%
 EOD+6 -2MRQTTM+0 -0YOY+29 -93Y+9 -295Y+9 -2910Y+9 -29

3.3 Fundamental Score

Let's check the fundamental score of Allergy Therapeutics based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-9.778
Price to Book Ratio (EOD)Between0-1106.021
Net Profit Margin (MRQ)Greater than0-0.729
Operating Margin (MRQ)Greater than0-0.635
Quick Ratio (MRQ)Greater than11.009
Current Ratio (MRQ)Greater than11.630
Debt to Asset Ratio (MRQ)Less than10.943
Debt to Equity Ratio (MRQ)Less than116.478
Return on Equity (MRQ)Greater than0.15-10.843
Return on Assets (MRQ)Greater than0.05-0.620
Total3/10 (30.0%)

3.4 Technical Score

Let's check the technical score of Allergy Therapeutics based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose7.910
Total0/1 (0.0%)

4. In-depth Analysis

4.1 About Allergy Therapeutics

Allergy Therapeutics plc, a commercial biotechnology company, focuses on the diagnosis and treatment of allergic disorders. The company sells injectable and sublingual allergen-specific immunotherapies; and offers treatment of pollen-related allergies particularly to grasses, weeds, and trees, as well as diagnostics products. Its products include Pollinex Quattro, Oralvac, Venomil, Venom ATL Polistes Dominula, Synbiotics, and Acarovac Plus. It also develops Grass MATA MPL, a subcutaneous allergen-specific immunotherapy candidate that aims to address the cause of symptoms of allergic rhinoconjunctivitis due to grass pollen; and VLP Peanut, a short-course peanut allergy vaccine. The company operates in Germany, Austria, Netherlands, Switzerland, Italy, Spain, and internationally, as well as the United Kingdom. Allergy Therapeutics plc was founded in 1998 and is headquartered in Worthing, the United Kingdom.

Fundamental data was last updated by Penke on 2025-06-26 22:03:08.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is just able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is just able to pay all its debts by selling its assets.
The company is unable to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is expensive.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profitย Allergy Therapeutics earns for each 1 of revenue.

  • Above 10% is considered healthy but always compareย Allergy Therapeutics to theย Drug Manufacturers - Specialty & Generic industry mean.
  • A Net Profit Margin of -72.9%ย means thatย -0.73 for each 1ย in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Allergy Therapeutics:

  • The MRQ is -72.9%. The company is making a huge loss. -2
  • The TTM is -72.9%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-72.9%TTM-72.9%0.0%
TTM-72.9%YOY-72.3%-0.6%
TTM-72.9%5Y-30.3%-42.5%
5Y-30.3%10Y-18.9%-11.5%
4.3.1.2. Return on Assets

Shows howย efficientย Allergy Therapeutics is using its assets to generate profit.

  • Above 5% is considered healthyย but always compareย Allergy Therapeutics to theย Drug Manufacturers - Specialty & Generic industry mean.
  • -62.0% Return on Assets means thatย Allergy Therapeutics generatedย -0.62 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Allergy Therapeutics:

  • The MRQ is -62.0%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -62.0%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-62.0%TTM-62.0%0.0%
TTM-62.0%YOY-64.5%+2.5%
TTM-62.0%5Y-26.8%-35.2%
5Y-26.8%10Y-17.1%-9.7%
4.3.1.3. Return on Equity

Shows how efficient Allergy Therapeutics is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compareย Allergy Therapeutics to theย Drug Manufacturers - Specialty & Generic industry mean.
  • -1,084.3% Return on Equity means Allergy Therapeutics generated -10.84ย for eachย 1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Allergy Therapeutics:

  • The MRQ is -1,084.3%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -1,084.3%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-1,084.3%TTM-1,084.3%0.0%
TTM-1,084.3%YOY-2,084.8%+1,000.5%
TTM-1,084.3%5Y-636.7%-447.6%
5Y-636.7%10Y-325.8%-310.9%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Allergy Therapeutics.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measuresย how efficient Allergy Therapeutics is operatingย .

  • Measures how much profit Allergy Therapeutics makes for each 1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compareย Allergy Therapeutics to theย Drug Manufacturers - Specialty & Generic industry mean.
  • An Operating Margin of -63.5%ย means the company generated -0.64 ย for each 1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Allergy Therapeutics:

  • The MRQ is -63.5%. The company is operating very inefficient. -2
  • The TTM is -63.5%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-63.5%TTM-63.5%0.0%
TTM-63.5%YOY-67.9%+4.4%
TTM-63.5%5Y-27.0%-36.5%
5Y-27.0%10Y-16.5%-10.5%
4.3.2.2. Operating Ratio

Measures how efficient Allergy Therapeutics is keepingย operating costsย low.

  • Below 1 is considered healthy (always compare toย Drug Manufacturers - Specialty & Generic industry mean).
  • An Operation Ratio of 1.64 means that the operating costs are 1.64 for each 1 in net sales.

Let's take a look of the Operating Ratio trends of Allergy Therapeutics:

  • The MRQ is 1.639. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1.639. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.639TTM1.6390.000
TTM1.639YOY1.585+0.054
TTM1.6395Y1.263+0.376
5Y1.26310Y1.163+0.100
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Allergy Therapeutics.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Allergy Therapeutics is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare toย Drug Manufacturers - Specialty & Generic industry mean).
  • A Current Ratio of 1.63ย means the company has 1.63 in assets for each 1 in short-term debts.

Let's take a look of the Current Ratio trends of Allergy Therapeutics:

  • The MRQ is 1.630. The company is able to pay all its short-term debts. +1
  • The TTM is 1.630. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ1.630TTM1.6300.000
TTM1.630YOY1.806-0.176
TTM1.6305Y2.397-0.767
5Y2.39710Y2.709-0.312
4.4.3.2. Quick Ratio

Measures if Allergy Therapeutics is able to pay off Short-term Debt but only usingย theย most liquid assets.

  • Above 1 is considered healthy butย always compareย Allergy Therapeutics to theย Drug Manufacturers - Specialty & Generic industry mean.
  • A Quick Ratio of 1.01ย means the company can pay off 1.01 for each 1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Allergy Therapeutics:

  • The MRQ is 1.009. The company is just able to pay all its short-term debts with the most liquid assets.
  • The TTM is 1.009. The company is just able to pay all its short-term debts with the most liquid assets.
Trends
Current periodCompared to+/- 
MRQ1.009TTM1.0090.000
TTM1.009YOY1.181-0.172
TTM1.0095Y1.786-0.776
5Y1.78610Y1.969-0.183
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Allergy Therapeutics.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much %ย of Allergy Therapeuticsย assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compareย Allergy Therapeutics to Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Asset Ratio of 0.94ย means that Allergy Therapeutics assets areย financed with 94.3% credit (debt) and the remaining percentage (100% - 94.3%)ย is financed by its owners/shareholders.ย 

Let's take a look of the Debt to Asset Ratio trends of Allergy Therapeutics:

  • The MRQ is 0.943. The company is just able to pay all its debts by selling its assets.
  • The TTM is 0.943. The company is just able to pay all its debts by selling its assets.
Trends
Current periodCompared to+/- 
MRQ0.943TTM0.9430.000
TTM0.943YOY0.969-0.026
TTM0.9435Y0.667+0.276
5Y0.66710Y0.560+0.107
4.5.4.2. Debt to Equity Ratio

Measures ifย Allergy Therapeutics is able toย pay off its debts by usingย shareholders equity.

  • Below 2 is considered healthy butย always compareย Allergy Therapeutics to theย Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Equity ratio of 1,647.8% means that company has 16.48 debt for each 1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Allergy Therapeutics:

  • The MRQ is 16.478. The company is unable to pay all its debts with equity. -1
  • The TTM is 16.478. The company is unable to pay all its debts with equity. -1
Trends
Current periodCompared to+/- 
MRQ16.478TTM16.4780.000
TTM16.478YOY31.318-14.840
TTM16.4785Y10.102+6.376
5Y10.10210Y5.480+4.623
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measuresย how much money you payย for each share forย every 1 in earnings Allergy Therapeutics generates.

  • Above 15 is considered overpriced butย always compareย Allergy Therapeutics to theย Drug Manufacturers - Specialty & Generic industry mean.
  • A PE ratio of -6.21 means the investor is paying -6.21ย for every 1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Allergy Therapeutics:

  • The EOD is -9.778. Based on the earnings, the company is expensive. -2
  • The MRQ is -6.210. Based on the earnings, the company is expensive. -2
  • The TTM is -6.210. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-9.778MRQ-6.210-3.567
MRQ-6.210TTM-6.2100.000
TTM-6.210YOY-0.981-5.230
TTM-6.2105Y85.691-91.901
5Y85.69110Y953.667-867.976
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Allergy Therapeutics:

  • The EOD is -11.065. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -7.028. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -7.028. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-11.065MRQ-7.028-4.037
MRQ-7.028TTM-7.0280.000
TTM-7.028YOY-1.406-5.621
TTM-7.0285Y40.536-47.563
5Y40.53610Y-26.827+67.363
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price ofย Allergy Therapeutics is to cheap or to expensiveย compared to its book value.

  • At or below 1 is considered healthyย (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • A PB ratio of 67.34 means the investor is paying 67.34ย for each 1 in book value.

Let's take a look of the Price to Book Ratio trends of Allergy Therapeutics:

  • The EOD is 106.021. Based on the equity, the company is expensive. -2
  • The MRQ is 67.339. Based on the equity, the company is expensive. -2
  • The TTM is 67.339. Based on the equity, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD106.021MRQ67.339+38.682
MRQ67.339TTM67.3390.000
TTM67.339YOY24.224+43.115
TTM67.3395Y31.509+35.830
5Y31.50910Y33.386-1.877
4.6.2. Total Gains per Share
3rd party ad coffee SUPPORTERis ad-free.

6. Financial Statements




6.1. Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2020-06-302021-06-302022-06-302023-06-302024-06-30
Current Deferred Revenue -1,519,500-13,800-1,533,300167,800-1,365,5001,185,200-180,300180,3000



6.2. Latest Balance Sheet

Balance Sheet of 2024-06-30. Currency in GBP. All numbers in thousands.

Summary
Total Assets64,827
Total Liabilities61,118
Total Stockholder Equity3,709
 As reported
Total Liabilities 61,118
Total Stockholder Equity+ 3,709
Total Assets = 64,827

Assets

Total Assets64,827
Total Current Assets33,482
Long-term Assets31,345
Total Current Assets
Cash And Cash Equivalents 12,915
Net Receivables 7,823
Inventory 12,744
Total Current Assets  (as reported)33,482
Total Current Assets  (calculated)33,482
+/-0
Long-term Assets
Property Plant Equipment 23,745
Goodwill 3,317
Intangible Assets 1,370
Long-term Assets Other 2,913
Long-term Assets  (as reported)31,345
Long-term Assets  (calculated)31,345
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities20,545
Long-term Liabilities40,573
Total Stockholder Equity3,709
Total Current Liabilities
Short-term Debt 2,116
Short Long Term Debt 600
Accounts payable 4,015
Other Current Liabilities 9,680
Total Current Liabilities  (as reported)20,545
Total Current Liabilities  (calculated)16,411
+/- 4,134
Long-term Liabilities
Long term Debt 22,500
Capital Lease Obligations 7,888
Long-term Liabilities  (as reported)40,573
Long-term Liabilities  (calculated)30,388
+/- 10,185
Total Stockholder Equity
Common Stock4,776
Retained Earnings -198,927
Accumulated Other Comprehensive Income 1,311
Other Stockholders Equity 196,549
Total Stockholder Equity (as reported)3,709
Total Stockholder Equity (calculated)3,709
+/-0
Other
Capital Stock4,766
Cash and Short Term Investments 12,915
Common Stock Shares Outstanding 3,743,332
Current Deferred Revenue0
Liabilities and Stockholders Equity 64,827
Net Debt 18,073
Net Invested Capital 26,809
Net Working Capital 12,937
Property Plant and Equipment Gross 54,264
Short Long Term Debt Total 30,988



6.3. Balance Sheets Structured

Currency in GBP. All numbers in thousands.

 Trend2024-06-302023-06-302022-06-302021-06-302020-06-302019-06-302018-06-302017-06-302016-06-302015-06-302014-06-302013-06-302012-06-302011-06-302010-06-302009-06-302008-06-302007-06-302006-06-302005-06-302004-06-302003-06-302002-06-30
> Total Assets 
9,676
11,149
11,234
26,660
37,880
23,994
23,183
22,077
29,115
30,621
27,754
28,964
28,398
50,699
56,679
57,183
51,016
68,497
86,225
88,089
72,948
66,769
64,827
64,82766,76972,94888,08986,22568,49751,01657,18356,67950,69928,39828,96427,75430,62129,11522,07723,18323,99437,88026,66011,23411,1499,676
   > Total Current Assets 
3,576
5,496
5,567
20,981
31,088
14,043
11,317
9,442
14,804
14,914
13,034
14,458
14,211
33,789
37,612
37,459
30,928
46,625
55,170
57,858
42,393
33,526
33,482
33,48233,52642,39357,85855,17046,62530,92837,45937,61233,78914,21114,45813,03414,91414,8049,44211,31714,04331,08820,9815,5675,4963,576
       Cash And Cash Equivalents 
56
1,267
1,457
15,080
23,860
5,696
2,298
0
4,520
1,048
903
1,257
2,029
21,199
23,406
22,122
15,533
27,440
36,962
40,273
20,515
14,845
12,915
12,91514,84520,51540,27336,96227,44015,53322,12223,40621,1992,0291,2579031,0484,52002,2985,69623,86015,0801,4571,26756
       Short-term Investments 
0
0
0
0
0
63
3
0
0
0
483
2
345
783
-10,331
404
0
0
0
0
0
0
0
0000000404-10,331783345248300036300000
       Net Receivables 
0
1,127
1,840
2,812
2,482
2,651
2,699
2,284
2,663
5,746
3,761
5,421
2,968
3,230
5,517
6,271
6,587
9,776
8,076
6,222
10,468
7,088
7,823
7,8237,08810,4686,2228,0769,7766,5876,2715,5173,2302,9685,4213,7615,7462,6632,2842,6992,6512,4822,8121,8401,1270
       Inventory 
1,865
1,915
1,825
2,741
3,651
4,911
5,817
6,002
6,894
7,087
6,651
6,014
6,469
6,747
7,692
7,484
8,808
9,409
10,132
10,838
11,410
11,593
12,744
12,74411,59311,41010,83810,1329,4098,8087,4847,6926,7476,4696,0146,6517,0876,8946,0025,8174,9113,6512,7411,8251,9151,865
       Other Current Assets 
1,655
2,314
2,285
348
1,095
722
500
1,156
727
1,033
1,236
4,039
2,400
1,830
1,777
3,461
2,760
5,284
4,585
3,787
7,774
4,722
0
04,7227,7743,7874,5855,2842,7603,4611,7771,8302,4004,0391,2361,0337271,1565007221,0953482,2852,3141,655
   > Long-term Assets 
6,100
5,653
5,667
5,679
6,792
9,951
11,866
12,635
14,311
15,707
14,720
14,506
10,801
13,750
15,022
15,132
15,045
16,321
31,055
30,231
30,555
33,243
31,345
31,34533,24330,55530,23131,05516,32115,04515,13215,02213,75010,80114,50614,72015,70714,31112,63511,8669,9516,7925,6795,6675,6536,100
       Property Plant Equipment 
1,342
1,221
1,650
2,111
3,637
5,486
6,883
7,191
8,938
8,809
7,555
7,337
7,030
8,750
9,667
9,673
10,096
11,481
20,417
19,717
20,190
23,241
23,745
23,74523,24120,19019,71720,41711,48110,0969,6739,6678,7507,0307,3377,5558,8098,9387,1916,8835,4863,6372,1111,6501,2211,342
       Goodwill 
0
3,220
2,945
2,617
4,977
2,295
2,468
2,555
2,496
2,624
2,489
2,560
2,480
2,980
3,271
3,390
3,406
3,432
3,467
3,343
3,347
3,346
3,317
3,3173,3463,3473,3433,4673,4323,4063,3903,2712,9802,4802,5602,4892,6242,4962,5552,4682,2954,9772,6172,9453,2200
       Intangible Assets 
4,758
4,432
4,017
951
-1,822
1,159
1,073
1,065
860
1,781
2,107
1,350
1,291
2,020
2,084
2,069
1,543
1,408
4,736
4,754
5,035
4,400
1,370
1,3704,4005,0354,7544,7361,4081,5432,0692,0842,0201,2911,3502,1071,7818601,0651,0731,159-1,8229514,0174,4324,758
       Other Assets 
0
0
0
0
0
0
1,400
1,824
2,017
2,493
2,569
3,259
3,386
3,160
4,045
4,592
5,043
5,551
0
5,760
0
5,813
0
05,81305,76005,5515,0434,5924,0453,1603,3863,2592,5692,4932,0171,8241,400000000
> Total Liabilities 
14,074
5,602
4,158
6,576
5,178
15,398
34,473
45,253
25,229
28,482
13,162
14,293
13,323
16,230
26,355
27,218
27,982
30,939
42,442
39,554
35,183
64,703
61,118
61,11864,70335,18339,55442,44230,93927,98227,21826,35516,23013,32314,29313,16228,48225,22945,25334,47315,3985,1786,5764,1585,60214,074
   > Total Current Liabilities 
4,593
3,997
3,277
6,121
4,939
10,864
8,105
21,774
9,984
11,147
7,747
7,620
6,474
7,420
12,520
14,020
14,631
16,859
18,227
18,230
18,053
18,565
20,545
20,54518,56518,05318,23018,22716,85914,63114,02012,5207,4206,4747,6207,74711,1479,98421,7748,10510,8644,9396,1213,2773,9974,593
       Short-term Debt 
0
500
278
0
0
0
2,422
11,652
1,109
2,793
1,426
288
49
251
295
391
644
694
2,264
1,755
2,268
1,803
2,116
2,1161,8032,2681,7552,264694644391295251492881,4262,7931,10911,6522,4220002785000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
49
251
295
391
644
694
829
963
952
648
600
60064895296382969464439129525149000000000000
       Accounts payable 
1,182
1,196
827
1,478
1,671
4,612
2,312
3,742
3,948
3,821
2,553
3,050
2,464
2,819
3,110
2,881
3,193
4,141
2,217
2,897
4,282
4,090
4,015
4,0154,0904,2822,8972,2174,1413,1932,8813,1102,8192,4643,0502,5533,8213,9483,7422,3124,6121,6711,4788271,1961,182
       Other Current Liabilities 
3,411
2,301
2,172
4,271
2,375
5,806
2,968
5,078
4,927
4,533
3,768
3,746
3,370
3,837
7,687
9,209
8,578
10,149
9,306
9,824
7,236
8,229
9,680
9,6808,2297,2369,8249,30610,1498,5789,2097,6873,8373,3703,7463,7684,5334,9275,0782,9685,8062,3754,2712,1722,3013,411
   > Long-term Liabilities 
9,481
1,605
881
455
239
4,534
26,368
23,479
15,245
17,335
5,415
6,673
6,849
1,433
3,070
2,936
2,414
1,742
24,215
21,324
17,130
46,138
40,573
40,57346,13817,13021,32424,2151,7422,4142,9363,0701,4336,8496,6735,41517,33515,24523,47926,3684,5342394558811,6059,481
       Other Liabilities 
0
241
214
455
239
2,373
2,955
4,224
4,649
4,773
5,153
6,514
6,713
7,377
10,765
10,262
10,937
12,338
14,300
11,907
8,869
19,532
0
019,5328,86911,90714,30012,33810,93710,26210,7657,3776,7136,5145,1534,7734,6494,2242,9552,3732394552142410
> Total Stockholder Equity
-6,457
5,547
7,076
20,084
32,702
8,596
-11,290
-23,176
3,886
2,139
14,592
14,671
15,075
34,469
30,324
29,965
23,034
37,558
43,783
48,535
37,765
2,066
3,709
3,7092,06637,76548,53543,78337,55823,03429,96530,32434,46915,07514,67114,5922,1393,886-23,176-11,2908,59632,70220,0847,0765,547-6,457
   Common Stock
48
51
51
73
92
92
92
92
321
321
417
420
410
546
589
594
596
636
647
651
654
689
4,776
4,7766896546516476365965945895464104204173213219292929273515148
   Retained Earnings -198,927-121,742-78,414-67,270-72,833-119,177-121,750-114,434-113,906-99,374-98,530-99,458-100,129-100,291-97,976-97,023-85,250-65,529-40,937-34,719-32,730-34,602-39,646
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
102,420
102,420
112,576
112,576
112,576
0
0
0
000112,576112,576112,576102,420102,420000000000000000
   Treasury Stock00000000000000000000000
   Other Stockholders Equity 
33,141
40,098
40,128
14,924
73,547
33,173
73,868
73,755
58,704
58,705
114,304
113,590
67,716
91,463
102,392
102,420
102,420
112,576
72,438
72,438
72,438
159,158
196,549
196,549159,15872,43872,43872,438112,576102,420102,420102,39291,46367,716113,590114,30458,70558,70473,75573,86833,17373,54714,92440,12840,09833,141



6.4. Balance Sheets

Currency in GBP. All numbers in thousands.




6.5. Cash Flows

Currency in GBP. All numbers in thousands.




6.6. Income Statements

Currency in GBP. All numbers in thousands.


6.7. Latest Income Statement

Income Statement (annual), 2024-06-30. Currency in GBP. All numbers in thousands.

Gross Profit (+$)
totalRevenue55,199
Cost of Revenue-25,462
Gross Profit29,73729,737
 
Operating Income (+$)
Gross Profit29,737
Operating Expense-64,994
Operating Income-35,257-35,257
 
Operating Expense (+$)
Research Development22,900
Selling General Administrative22,790
Selling And Marketing Expenses19,591
Operating Expense64,99465,281
 
Net Interest Income (+$)
Interest Income285
Interest Expense-4,107
Other Finance Cost-87
Net Interest Income-3,909
 
Pretax Income (+$)
Operating Income-35,257
Net Interest Income-3,909
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-39,166-31,348
EBIT - interestExpense = -39,166
-39,166
-36,109
Interest Expense4,107
Earnings Before Interest and Taxes (EBIT)-35,059-35,059
Earnings Before Interest and Taxes (EBITDA)-30,740
 
After tax Income (+$)
Income Before Tax-39,166
Tax Provision-1,050
Net Income From Continuing Ops-40,216-40,216
Net Income-40,216
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses90,456
Total Other Income/Expenses Net-3,9093,909
 

Technical Analysis of Allergy Therapeutics
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Allergy Therapeutics. The general trend of Allergy Therapeutics is UNKNOWN with 0.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Allergy Therapeutics's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator StateBullish trend Bearish trend
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Allergy Therapeutics Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Supportย is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistanceย is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Allergy Therapeutics.

The long score for the Support & Resistance is 1/1.
The longshort score for the Support & Resistance is 1/(-1 +1).

  • Around support: The price is currently trading around a support level. This can be considered as a potential entry level. +1

The bullish price targets are: .

The bearish price targets are: 8 > 8 > 8.

Know someone who trades $AGY? Share this with them.๐Ÿ‘‡

Allergy Therapeutics Daily Support & Resistance Chart
3rd party ad coffee SUPPORTERis ad-free.

2. Trend Indicators

2.1 Moving Averages

Shows theย moving averageย of the selected period.

  • Moving averages are laggingย trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Allergy Therapeutics. The current mas is .

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Allergy Therapeutics Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows theย momentumย of theย selected period based on two moving averages.

  • MACD is aย lagging momentumย indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Allergy Therapeutics.

Allergy Therapeutics Daily Moving Average Convergence/Divergence (MACD) ChartAllergy Therapeutics Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Allergy Therapeutics. The current adx is .

Allergy Therapeutics Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Showsย the current trend.
  • Showsย potential entry signals.
  • Showsย ย potential exit signals.
  • Can be used to placeย trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Allergy Therapeutics.

Allergy Therapeutics Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentumย indicator, meaning the signals are instant.
  • Rangesย between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Allergy Therapeutics.

Allergy Therapeutics Daily Relative Strength Index (RSI) ChartAllergy Therapeutics Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Comparesย a certain price to multiple prices ranging over time.

  • Leadingย momentumย indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Rangesย between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Allergy Therapeutics.

Allergy Therapeutics Daily Stochastic Oscillator ChartAllergy Therapeutics Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero,ย the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Allergy Therapeutics.

Allergy Therapeutics Daily Commodity Channel Index (CCI) ChartAllergy Therapeutics Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Allergy Therapeutics.

Allergy Therapeutics Daily Chande Momentum Oscillator (CMO) ChartAllergy Therapeutics Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

ย Shows the current price relative to the highest high over the last 14 days.
ย 

  • Lagging momentum indicator
  • Ranging between 0 andย -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Allergy Therapeutics.

Allergy Therapeutics Daily Williams %R ChartAllergy Therapeutics Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversoldย 

Score

Let's take a look at the Bollinger Bands of Allergy Therapeutics.

Allergy Therapeutics Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Allergy Therapeutics.

Allergy Therapeutics Daily Average True Range (ATR) ChartAllergy Therapeutics Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

ย Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Allergy Therapeutics.

Allergy Therapeutics Daily On-Balance Volume (OBV) ChartAllergy Therapeutics Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Allergy Therapeutics.

Allergy Therapeutics Daily Money Flow Index (MFI) ChartAllergy Therapeutics Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Allergy Therapeutics.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2025-02-18MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-02-19STOCH LONG EXITThe %K line crosses below the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-02-20STOCH SHORT EXITThe %K line crosses above the %D line.
2025-02-21WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-02-24STOCH LONG EXITThe %K line crosses below the %D line.
2025-02-25STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-02-26STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-02-27STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-02-28STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-03-03SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-03-05MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-03-07STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-11SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-12MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-03-13SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-03-17STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-03-18STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-03-19SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-03-20SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-03-21STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-25MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-03-27STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-28STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-31CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-04-01STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-03STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-04STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-08STOCH LONG EXITThe %K line crosses below the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-04-10MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-04-11WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-04-14STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-16SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2025-04-22MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-04-24DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-04-25DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2025-04-28DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-04-30DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-01DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2025-05-02STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-05-06SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2025-05-07SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2025-05-08STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-12CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-05-15CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-05-19STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-20STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-21MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-22STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-23MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2025-05-27STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-29MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-05-30STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-06-02DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-06-03DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2025-06-05STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-06-06STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-06-09STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-06-10STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-06-11DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-06-12CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-06-13STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-06-16MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-06-17MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-18CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-06-19MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-06-23SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-06-24SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2025-06-25MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2025-06-26STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-06-30DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-07-02STOCH LONG EXITThe %K line crosses below the %D line.

6.3. Candlestick Patterns

Allergy Therapeutics Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Allergy Therapeutics based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose7.910
Total0/1 (0.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Allergy Therapeutics with someone you think should read this too:
  • Are you bullish or bearish on Allergy Therapeutics? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Allergy Therapeutics? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Allergy Therapeutics

I send you an email if I find something interesting about Allergy Therapeutics.


Comments

How you think about this?

Leave a comment

Stay informed about Allergy Therapeutics.

Receive notifications about Allergy Therapeutics in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.